Everolimus is an oral mTOR inhibitor derived from sirolimus, which had been approved by FDA in the treatment of patients with TSC-AML and adult patients with TSC-subependymal giant cell astrocytoma44, and the improved pharmacokinetic profile of everolimus over sirolimus makes it an attractive, noninvasive option for patients. This evidence concerns the gene MTOR and acute myeloid leukemia.